Dopamine Agents
This graph shows the total number of publications written about "Dopamine Agents" by people in the URMC Research Network by year, and whether "Dopamine Agents" was a major or minor topic of these publication.
Below are the most recent publications written about "Dopamine Agents" by people in Profiles.
-
Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar; 26(4):608-13.
-
Repka MX, Kraker RT, Beck RW, Atkinson CS, Bacal DA, Bremer DL, Davis PL, Gearinger MD, Glaser SR, Hoover DL, Laby DM, Morrison DG, Rogers DL, Sala NA, Suh DW, Wheeler MB. Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Arch Ophthalmol. 2010 Sep; 128(9):1215-7.
-
Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
-
Mink JW, Zinner SH. Movement disorders ii: chorea, dystonia, myoclonus, and tremor. Pediatr Rev. 2010 Jul; 31(7):287-94; quiz 295.
-
Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, Ellis RJ, Kolson DL, Simpson D, Miller EN, Lipton SA, Evans SR, Schifitto G. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010 Jan-Feb; 11(1):59-67.
-
Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand. 2009 May; 119(5):345-8.
-
Tivarus ME, Hillier A, Schmalbrock P, Beversdorf DQ. Functional connectivity in an fMRI study of semantic and phonological processes and the effect of L-Dopa. Brain Lang. 2008 Jan; 104(1):42-50.
-
Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006 Oct 25; 248(1-2):78-83.
-
Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
-
Tieu K, Perier C, Vila M, Caspersen C, Zhang HP, Teismann P, Jackson-Lewis V, Stern DM, Yan SD, Przedborski S. L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Ann Neurol. 2004 Jul; 56(1):51-60.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
